Market Update: Allergan Inc (NYSE:AGN) – Amgen, Allergan biosimilar found as effective as Roche cancer drug

[Reuters] – Amgen Inc and Allergan Plc said their copycat version of Roche Holding AG’s blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study. There were no “clinically meaningful” differences in data gathered from patients given Herceptin and the copycat version, ABP 980, to treat a type of early breast cancer, said Sean Harper, Amgen’s executive vice president of research and development. Read more on this. , currently valued at $recting to http://finance.ya, finished at $. Looking at the stock, its one day range is $ with a one year range of $. Priced at x this year’s forecasted earnings, AGN shares are relatively inexpensive compared to the industry’s x forward p/e ratio. In a review of the consensus earnings estimate this quarter, 0 sell-side analysts are looking at $ per share, which would be $0.00 worse than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $ which would be a $0.00 setback than last year’s full-year earnings. The quarterly earnings estimate is predicated on a consensus revenue forecast of $0.00 . If reported, that would be a 0.00% decrease over the year-ago quarter. In terms of ratings, d AGN from to (/fi). Previously, d AGN from to . When considering if the stock is under or overvalued, the average price target is $, which is 0.00% below where the stock opened this morning. See more in (NYSE:AGN) Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer Stock Update: Allergan Inc (NYSE:AGN) – Allergan Announces FDA Approval of Supplemental New Drug Application (sNDA) for AVYCAZ® (ceftazidime and avibactam) Stock Update: Amgen Inc (NASDAQ:AMGN) – UK cost agency rejects Amgen’s virus-based cancer drug